Bioinformatics driven in gene targeting platform for gold anticancer strategy delivery.

Area of Science:

• Oncology
• Molecular Biology
• Nanotechnology

Background:

• Triple-negative breast cancer (TNBC) is highly aggressive with limited targeted therapies.
• Current TNBC treatment relies heavily on chemotherapy, highlighting the need for novel therapeutic strategies.
• Identifying specific molecular targets and effective delivery systems is crucial for advancing TNBC treatment.

Purpose of the Study:

• To identify novel therapeutic targets in TNBC.
• To develop an effective nucleic acid delivery system for TNBC treatment.
• To elucidate the role of SDC1 in TNBC progression and drug resistance.

Main Methods:

• Gene chip data screening to identify differentially expressed genes in TNBC.
• Single-cell RNA sequencing (scRNA-seq) to analyze SDC1-dependent changes in the tumor microenvironment (TME).
• Construction of an in situ self-reactive gold nanocluster SDC1 shRNA-targeted nucleic acid delivery system.

Main Results:

• SDC1 was identified as a highly expressed gene in TNBC, correlating with poorer overall survival.
• Increased SDC1 expression was associated with etoposide drug resistance in TNBC.
• The developed gold nanocluster system effectively inhibited TNBC angiogenesis by targeting SDC1.
• SDC1 was found to promote tumor progression via modulation of the TNBC microenvironment.

Conclusions:

• SDC1 is a potential therapeutic target for TNBC, implicated in tumor progression and drug resistance.
• A bioinformatics-driven platform can facilitate the rational design of nanocluster-based anticancer strategies.
• Targeted nucleic acid delivery systems, like the gold nanocluster developed, show promise for inhibiting TNBC growth and angiogenesis.